Forbion Attracts New Investors Closing IV Fund At €360M

European life science companies can expect to get access to almost €290m from Forbion as the EU-based venture capitalist closes its fourth fund at an oversubscribed €360m.

Forbion, a leading European life science venture capital firm, today announced the final close of its new flagship fund, Forbion IV, at €360m in capital commitments, significantly above its original target of €250m. New investors include UK-based Pantheon, Dutch institutions ASR Insurances and the TNO Pension Fund, Nordic investors Formuesforvaltning and KLP, and some undisclosed North American institutional investors. Existing limited partners (LPs) European Investment Fund and development bank KfW also returned as backers of the new fund.

Forbion IV, like its predecessor fund, Forbion III, will primarily focus on biopharma opportunities in the EU including the UK,...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Financing

Vor Is Reborn With New CEO And Ambitious RemeGen Autoimmune Pact

 
• By 

The biotech had been looking at options to survive since May.

Stock Watch: When The Biotech Bandwagon Music Stops

 
• By 

The number of viable biotech companies exploiting a particular technology should be limited by intellectual property but the number of biotech IPOs exploiting that same technology always seems greater than those with freedom to operate.

China Signals Restarting IPOs For Unprofitable Biotechs

 

The China Securities Regulatory Commission has proposed a new “growth tier” for the STAR Market of the Shanghai Stock Exchange, to reinstate the market’s listing standards for unprofitable firms.

BIO Notebook: Woodcock Calls For Doing The Right Thing, Dealmaking Remains Constrained

 

Highlights from Day Four of the BIO International Convention include Woodcock offering practical advice on rare disease trials, the sorry state of dealmaking mid-year, Novartis discussing its approach to partnering, and Generate looking for funding to move into Phase III.

More from Business

Snapshot Of India’s Pharma Manufacturing Network Amid ‘Trumponomics’

 

Scrip collates data on the global manufacturing network of leading Indian drug makers, the markets serviced and production hubs for active pharmaceutical ingredients. Will ongoing geopolitical tensions and policy shifts have a bearing on some of these down the line?

GSK, Bharat On Shigella Vaccine Phase II Data Timelines, Malaria Vaccine Price Halving

 
• By 

GSK tells Scrip about timelines for data expected from two Phase II trials for its Bharat Biotech-partnered shigella vaccine candidate, which puts it ahead of Limmatech/Valneva. Meanwhile, a global-first malaria vaccine, also partnered with Bharat, sees an over 50% price cut

US Tariff Overhang Weighs on Chinese API Exports

 

Chinese API exports to the US fell by 24% year-on-year to $255m in May, when the US and China called a truce in a previously escalating trade war.